Ribavirin, a synthetic nucleoside antiviral agent, is used for the treatment of respiratory syncytial virus infections in infants (2-4, 8, 9) . Ribavirin aerosol is created by a smallparticle aerosol generator, with delivery of aerosol by mist tent, hood, or ventilator. Toxicity data regarding teratogenicity and embryolethality in certain small animals dosed systemically with ribavirin were cited at the time this drug was approved for use in pediatrics in the United States in 1986 (Virazole package insert, January 1986, ICN Pharmaceuticals Inc., Irvine, Calif.). Concerns over health care worker (HCW) exposure to aerosolized ribavirin led to a clinical study by Rodriguez et al. (7) of 18 hospital personnel in whom neither plasma nor erythrocytes (RBC) contained detectable ribavirin. Harrison and co-workers (5) raised questions regarding HCW exposure to ribavirin aerosol at the conclusion of a similar study in which ribavirin was detected in a single RBC sample in 1 of 10 personnel tested. In addition to biological sampling, room air concentrations of ribavirin were also measured (5 across the room, and in the PBZ were 3, 4, and 3 ,ug/m3, respectively. Of 14 exposed HCW, 7 consented to give plasma and RBC for ribavirin assay. One of the seven personnel wore a face mask that was considered capable of filtering ribavirin during contact with the aerosol. Ribavirin was not detected in plasma and RBC samples of any personnel tested.
We evaluated the effectiveness of the ADH in decreasing room air levels of ribavirin in a clinical setting. Other vacuum exhaust aerosol delivery devices are currently under study (National Institute for Occupational Safety and Health, Centers for Disease Control, Atlanta, Ga., 30 June 1989). We found that concentrations of ribavirin in room air generally corresponded to those published by Harrison et al. (5) for delivery of ribavirin either by oxygen hood or by ventilator. The ADH was shown to reduce room air levels of ribavirin substantially, although wide variations in room and PBZ levels were seen. These variations were likely to be due to several factors: (i) inadequate room ventilation, (ii) HCW entering the ADH without first stopping aerosol delivery into the hood, (iii) air sampler exposure to aerosol streams, or (iv) position of the hood with respect to room ventilation outlets.
These data confirm, in a clinical setting, that ribavirin concentrations in room air can be substantially lowered when the delivery of aerosol is accompanied by a system designed to remove and filter the aerosol during treatment. However, such devices may prove to be more effective if education for HCW includes specific instructions to stop the nebulizing airflow prior to opening the hood. Lower concentrations of ribavirin in room air will decrease the risk of absorption of ribavirin by HCW as well as other people present in the room of a child being treated with aerosol.
A safe level of ribavirin aerosol exposure among HCW is yet to be determined. Harrison et al. chose to follow a convention established by the Environmental Protection Agency in 1986 (10). However, in a more recently published guideline by this agency (11), a factor of 10 for intraspecies variation (human) was suggested, as well as a factor of 10 for interspecies variation, with an additional factor "for scientific uncertainties that may exist in the available data base." Because substantial experimental animal data exist, it may be more appropriate to use a total 100-fold reduction below the NOAEL. Other standards, such as that proposed by Johnson (6) , support a total uncertainty factor of 100 as being more appropriate for evaluating human exposure to potentially toxic agents. Given these assumptions, controlling exposure to ribavirin during aerosol delivery by ventilator or by ADH will result in a total environmental exposure which would be considered acceptable by these standards.
As any model is at best a theoretical predictor of toxicity, it is still appropriate to reduce environmental exposure to potentially toxic drugs to the lowest possible level. Our limited data suggest that the ADH and mechanical ventilation are both effective in reducing environmental levels of ribavirin significantly compared with oxygen hood administration. Further studies on HCW exposure to ribavirin aerosol delivered by the ADH vacuum exhaust system, as well as by systems designed for children who weigh more than 5 kg and who do not require mechanical ventilation, are clearly needed. VOL. 34, 1990 on August 14, 2017 by guest http://aac.asm.org/ Downloaded from
